BUSINESS
Biocon Surges as Biocon Biologics Launches Yesintek (ustekinumab-kfce) in the U.S.
Biocon’s stock is witnessing a sharp rally following the launch of Yesintek (ustekinumab-kfce) in the United States by its subsidiary Biocon Biologics. The company’s shares are currently trading…


